Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2022; 14(03): 253-259
DOI: 10.1055/s-0042-1742418
Original Article

Association of Serum Cyclophilin A Levels with Severity of Coronary Artery Disease

Namilakonda Manaswini 
1   Department of Biochemistry, ESIC Medical College and Hospital, Hyderabad, Telangana, India
,
Neelam N. Sreedevi
2   Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Sabitha Thummala
2   Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Kompella S.S. Saibaba
2   Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Noorjahan Mohammed 
2   Department of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
,
Oruganti Sai Satish
3   Department of Cardiology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
› Author Affiliations Funding This study was self-funded.
› Further Information
   Permissions and Reprints

Abstract

Objective The disequilibrium between oxidant and antioxidant systems causes oxidative stress. Further, it disrupts the cell and releases reactive oxygen species (ROS), which in turn damages the vascular functions. Cyclophilin A (CypA), an immunophilin, is released in a highly regulated manner from vascular smooth muscle cells and multiplies the deleterious effects of ROS, associated with cardiovascular diseases. Thus, the aim of the present study is to correlate serum CypA levels with the severity of coronary artery disease (CAD).

Materials and Methods Study participants composed of 103 adult subjects, among whom 73 subjects were cases who were diagnosed as CAD angiographically. Thirty years of age and gender-matched subjects were taken as controls. The cases were further divided into single, double, and triple vessel disease subgroups. Blood samples were collected for the estimation of serum CypA, malondialdehyde (MDA), high-sensitive C-reactive protein (hsCRP), lipid profile, and plasma-glycated hemoglobin (HbA1C) by relevant biochemical methods.

Statistical Analysis The analysis was done using SPSS version 25. The data were expressed as median/mean and interquartile range/standard error. The groups were compared using the Mann–Whitney U-test and the Kruskal–Wallis test. p-Value less than 0.05 was considered statistically significant. Comparison of area under the curve (AUC) in receiver operating characteristic (ROC) curves was performed. A correlation was done by Spearman rank correlation.

Results The mean levels of serum CypA, hsCRP, and MDA in cases were significantly higher than those of controls (38 vs. 27 ng/mL, 18 vs. 5.1 mg/L, and 26 vs. 14 nmol/mL, p < 0.001). A positive correlation was observed between serum levels of CypA versus hsCRP and CypA versus MDA (r = 0.36 p = 0.00, r = 0.52, p = 0.00). At cut-off values greater than 33 ng/mL and 2.1 mg/L, serum CypA and hsCRP have 71% sensitivity, 93% specificity (AUC = 0.83), 84% sensitivity, and 70% specificity (AUC = 0.78) respectively. The number of occluded vessels was positively correlated with both CypA and hsCRP. Also, Serum CypA showed a significant positive correlation with HbA1C.

Conclusion Serum CypA can be used as a valuable biomarker for CAD.

Keywords

cyclophilin A - hsCRP - malondialdehyde - coronary artery disease - sensitivity - biomarker

Ethical Clearance

The study was approved by the hospital's institutional ethical committee (EC/NIMS/1673/2015).




Publication History

Article published online:
15 February 2022

© 2022. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Krishnan MN. Coronary heart disease and risk factors in India - on the brink of an epidemic?. Indian Heart J 2012; 64 (04) 364-367
    CrossrefPubMedGoogle Scholar
  • 2 Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016; 118 (04) 535-546
    CrossrefPubMedGoogle Scholar
  • 3 Bhat MA, Mahajan N, Gandhi G. Oxidative stress status in coronary artery disease patients. IJLBPR 2012; 1: 2250-3137
    Google Scholar
  • 4 Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res 2006; 98 (06) 811-817
    CrossrefPubMedGoogle Scholar
  • 5 Satoh K, Fukumoto Y, Sugimura K. et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J 2013; 77 (02) 447-455
    CrossrefPubMedGoogle Scholar
  • 6 Jin ZG, Melaragno MG, Liao DF. et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res 2000; 87 (09) 789-796
    CrossrefPubMedGoogle Scholar
  • 7 Tristano AG, Castejon AM, Castro A, Cubeddu LX. Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 2007; 353 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 8 Pan H, Luo C, Li R. et al. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem 2008; 283 (01) 623-637
    CrossrefPubMedGoogle Scholar
  • 9 Zhu C, Wang X, Deinum J. et al. Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med 2007; 204 (08) 1741-1748
    CrossrefPubMedGoogle Scholar
  • 10 Nigro P, Pompilio G, Capogrossi MC. Cyclophilin A: a key player for human disease. Cell Death Dis 2013; 4 (10) e888-e888
    CrossrefPubMedGoogle Scholar
  • 11 Satoh K, Matoba T, Suzuki J. et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation 2008; 117 (24) 3088-3098
    CrossrefPubMedGoogle Scholar
  • 12 Satoh K, Nigro P, Matoba T. et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009; 15 (06) 649-656
    CrossrefPubMedGoogle Scholar
  • 13 Weintraub NL. Understanding abdominal aortic aneurysm. N Engl J Med 2009; 361 (11) 1114-1116
    CrossrefPubMedGoogle Scholar
  • 14 Nigro P, Satoh K, O'Dell MR. et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011; 208 (01) 53-66
    CrossrefPubMedGoogle Scholar
  • 15 Rezzani R, Favero G, Stacchiotti A, Rodella LF. Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin. Life Sci 2013; 92 (17–19): 875-882
    CrossrefPubMedGoogle Scholar
  • 16 Seizer P, Schönberger T, Schött M. et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010; 209 (01) 51-57
    CrossrefPubMedGoogle Scholar
  • 17 Zaki MM, Mohsen M, Shaaban MA, Sedky RM. Study of serum levels of cyclophilin A in patients with coronary artery disease. QJM: Int J Med 2020; 113 (Issue Suppl 1): hcaa061.002
    CrossrefGoogle Scholar
  • 18 Hussain M, Mohammed E, El-Sherbeny A, Shehata A. Cyclophilin A: a novel biomarker for cardiovascular disease in patients with type 2 diabetes. Egypt J Intern Med 2019; 31 (04) 416
    CrossrefGoogle Scholar
  • 19 Ohtsuki T, Satoh K, Omura J. et al. Prognostic impacts of plasma levels of cyclophilin A in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2017; 37 (04) 685-693
    CrossrefPubMedGoogle Scholar
  • 20 Alfonso A, Bayón J, Gegunde S. et al. High serum cyclophilin C levels as a risk factor marker for coronary artery disease. Sci Rep 2019; 9 (01) 10576
    CrossrefPubMedGoogle Scholar
  • 21 Yan J, Zang X, Chen R. et al. The clinical implications of increased cyclophilin A levels in patients with acute coronary syndromes. Clin Chim Acta 2012; 413 (7–8): 691-695
    CrossrefPubMedGoogle Scholar
  • 22 Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol 2004; 24 (07) 1186-1191
    CrossrefPubMedGoogle Scholar
  • 23 Vinitha A, Kutty VR, Vivekanand A. et al. PPIA rs6850: A > G single-nucleotide polymorphism is associated with raised plasma cyclophilin A levels in patients with coronary artery disease. Mol Cell Biochem 2016; 412 (1–2): 259-268
    CrossrefPubMedGoogle Scholar
  • 24 Yossef AA, Issa HA, Ahmad ES, Farag SE, Abd El Bar NA. Assessment of plasma level of cyclophilin A in type 2 diabetic patients suffering from vascular diseases. Benha Med J 2018; 35 (02) 188-193
    CrossrefGoogle Scholar
  • 25 Noshin TF, Ali MR, Banik S. Increased oxidative stress and altered serum macro-minerals and trace elements levels are associated with coronary artery disease. J Trace Elem Med Biol 2021; 64: 126707
    CrossrefPubMedGoogle Scholar
  • 26 Khaki Khatibi F, Yaghoubi A, Zarghami N, Rahbani M, Babaei H. Evaluation of hs-CRP, antioxidant markers and MDA in patients of coronary artery disease (CAD) containing non-smokers and non-diabetics. J Cardiovasc Thorac Res 2011; 2: 13-18
    Google Scholar
  • 27 Uppal N, Uppal V, Uppal P. Progression of coronary artery disease (CAD) from stable angina (SA) towards myocardial infarction (MI): role of oxidative stress. J Clin Diagn Res 2014; 8 (02) 40-43
    PubMedGoogle Scholar
  • 28 Mutlu-Türkoğlu U, Akalin Z, Ilhan E. et al. Increased plasma malondialdehyde and protein carbonyl levels and lymphocyte DNA damage in patients with angiographically defined coronary artery disease. Clin Biochem 2005; 38 (12) 1059-1065
    CrossrefPubMedGoogle Scholar
  • 29 Stocker R, Keaney Jr JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84 (04) 1381-1478
    CrossrefPubMedGoogle Scholar
  • 30 Guruprasad S, Rajasekhar D, Subramanyam G, Srinivasa Rao PVLN, Vanajakshamma V, Latheef K. High sensitivity C-reactive protein levels across spectrum and severity of coronary artery disease. J Clin Sci Res 2012; 1 (03) 126-130
    CrossrefGoogle Scholar
  • 31 Rashidinejad H, Moazanzadeh M, Mirshekarpoor H, Ebrahimi F. The relationship between HS-CRP serum levels with the results of cardiac perfusion SPECT imaging in patients with suspected coronary artery disease. Asian J Biomed Pharm Sci 2015; 5 (50) 30-33
    Google Scholar
  • 32 Ramachandran S, Venugopal A, Kutty VR. et al. Plasma level of cyclophilin A is increased in patients with type 2 diabetes mellitus and suggests presence of vascular disease. Cardiovasc Diabetol 2014; 13 (01) 38
    CrossrefPubMedGoogle Scholar